Nebinad (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which reduces heart rate and contractile force, leading to lower cardiac output and blood pressure. Additionally, it enhances endothelial nitric oxide production, causing vasodilation that further contributes to its antihypertensive effect without significant β2‑receptor blockade.

The dose of Nebinad is individualized by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any comorbidities. Physicians determine the appropriate starting dose and any subsequent titration according to current treatment guidelines and patient tolerance.

Safety data for nebivolol during pregnancy and lactation are limited, and the medication is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare provider.

To order Nebinad, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nebivolol is distinguished by its high β1‑selectivity and additional nitric‑oxide‑mediated vasodilatory properties, which can result in fewer metabolic side effects compared with non‑selective beta blockers. While all beta blockers lower heart rate and blood pressure, nebivolol’s vasodilatory effect may offer better tolerability in some patients, especially those with peripheral vascular concerns.

Nebinad tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Nebinad is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include severe bradycardia, atrioventricular block, marked hypotension, bronchospasm in patients with reactive airway disease, and rare cases of hepatic dysfunction or allergic reactions. Patients should be monitored for symptoms such as fainting, chest discomfort, difficulty breathing, or unusual skin reactions and seek immediate medical attention if they occur.

Nebinad is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia (resting heart rate < 60 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or cardiogenic shock. Caution is also advised for patients with severe hepatic impairment.